Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Vernalis plc
Vernalis plc
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Three milestones in Servier and Vernalis oncology drug discovery collaboration
Two research milestones and one clinical milestone, triggering a total payment of €2m to Vernalis
Research & Development
Servier and Vernalis announce three milestones in their oncology drug discovery collaboration
Two research milestones and one clinical milestone reached, triggering a total payment of €2 million to Vernalis
Research & Development
Vernalis and Servier enter drug discovery collaboration
Vernalis and Servier will enter into a new two-year oncology drug discovery collaboration on an undisclosed target
Regulatory
FDA accepts CCP-08 NDA for full review
PDUFA date of 4 August 2017
Research & Development
Sandford Sommer joins Vernalis as President & Chief Operating Officer
Prior to joining the UK firm Sommer spent 24 years at AstraZeneca
Research & Development
Pharmaceutical industry rewarded in Queen\'s Awards for Enterprise 2014
Four companies honoured for International Trade and two for Innovation
Subscribe now